ropivacaine rinn roʊˈpɪvəkeɪn local anaesthetic drug belonging amino amide group name ropivacaine refers racemate marketed senantiomer ropivacaine hydrochloride commonly marketed astrazeneca brand name naropin ropivacaine developed bupivacaine noted associated cardiac arrest particularly pregnant women ropivacaine found less cardiotoxicity bupivacaine animal models ropivacaine contraindicated intravenous regional anaesthesia ivra however new data suggested ropivacaine mgkg levobupivacaine ml solution used less cardiovascular central nervous system toxicity racemic adverse drug reactions adrs rare administered correctly adrs relate administration technique resulting systemic exposure pharmacological effects anesthesia however allergic reactions rarely occur systemic exposure excessive quantities ropivacaine mainly result central nervous system cns cardiovascular effects cns effects usually occur lower blood plasma concentrations additional cardiovascular effects present higher concentrations though cardiovascular collapse may also occur low concentrations cns effects may include cns excitation nervousness tingling around mouth tinnitus tremor dizziness blurred vision seizures followed depression drowsiness loss consciousness respiratory depression apnea cardiovascular effects include hypotension bradycardia arrhythmias andor cardiac arrest may due hypoxemia secondary respiratory ropivacaine toxic cartilage intraarticular infusions lead postarthroscopic glenohumeral bupivacaine celepid commonly available intravenous lipid emulsion effective treating severe cardiotoxicity secondary local anaesthetic overdose animal humans process called lipid httpsenwikipediaorgwikiropivacaine